Osteomielitis crónica no bacteriana: experiencia en un hospital terciario / Non-bacterial chronic osteomyelitis: Experience in a tertiary hospital

INTRODUCCIÓN: La osteítis crónica no bacteriana (OCNB) es una enfermedad autoinflamatoria que cursa con brotes de inflamación ósea en ausencia de aislamiento microbiológico. Su diagnóstico es de exclusión. El tratamiento se basaba en la utilización de antiinflamatorios no esteroideos (AINE) y esteroideos aunque cada vez con mayor frecuencia se utilizan bifosfonatos o fármacos contra el factor de necrosis tumoral α (anti-TNFα) con buenos resultados. El objetivo es revisar nuestra experiencia en el diagnóstico y tratamiento de estos pacientes. PACIENTES Y MÉTODOS: Revisión retrospectiva de las historias clínicas de los pacientes diagnosticados de OCNB entre 2008 y 2015 en un hospital terciario. RESULTADOS: De un total de 7 pacientes, 4 eran mujeres, con una mediana de edad de 10 años (RIQ 2). El motivo más frecuente de consulta fue dolor que interfería con el sueño en 5 pacientes. Seis presentaron lesiones multifocales al diagnóstico. En 6 se realizó biopsia ósea que demostró un infiltrado neutrofílico o linfocitario y esclerosis. Cuatro pacientes recibieron tratamiento antibiótico y AINE sin respuesta clínica. Cinco pacientes recibieron prednisona, consiguiéndose control sintomático que solo mantuvo uno tras su suspensión. Cinco recibieron bifosfonatos con remisión de la enfermedad en 3. Dos pacientes presentaron una respuesta insuficiente a pamidronato, por lo que recibieron terapia anti-TNFα (etanercept, infliximab o adalimumab) y se mantienen asintomáticos en la actualidad. CONCLUSIONES: Nuestra serie, aunque limitada, confirma la efectividad y seguridad de la terapia con bifosfonatos y fármacos biológicos en pacientes con OCNB

INTRODUCTION: Non-bacterial chronic osteomyelitis (NBCO) is an autoinflammatory disease that presents with recurrent bouts of bone inflammation in the absence of microbiological isolation. It is a diagnosis of exclusion. Its treatment was classically based on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, although nowadays bisphosphonates or anti-tumour necrosis factor-α (anti-TNF) drugs are frequently used with good results. The objective of the study is to describe our experience in the diagnosis and treatment of patients with NBCO. PATIENTS AND METHODS: Retrospective chart review of patients with NBCO followed up in a tertiary centre between 2008 and 2015. RESULTS: A total of 7 patients with NBCO were recorded. Four were female and the median age was 10 years (IQR 2). The most common complaint was pain that interfered with sleep in 5 of the patients. Six patients had multifocal lesions at diagnosis. Bone biopsy demonstrated neutrophilic or lymphocytic infiltration and sclerosis in 6 patients. Four patients received antibiotics and NSAIDs without clinical response. Five received a short course of prednisone with an adequate control of symptoms, but only one of them maintained remission after corticosteroid suspension. Five patients received bisphosphonates with disease remission in 3 of them. The other 2 showed an inadequate response to pamidronate and were started on anti-TNF therapy (etanercept, infliximab or adalimumab), remaining asymptomatic at present. CONCLUSIONS: Our series, although limited, confirms the effectiveness and safety of bisphosphonate and anti-TNF therapy for children with NBCO

Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.

BACKGROUND AND AIM: A small but significant proportion of patients with normal body mass index show non-alcoholic fatty liver disease (NAFLD). Oxidized low-density lipoprotein (LDL) is a powerful immunogenic molecule, which causes oxidative stress and produces antibodies (oxLDL-ab). We aimed to analyze the role of oxLDL-ab on histological features in lean-NAFLD patients. METHODS: Seventy-two biopsy-proven NAFLD patients were included. Lean patients showed body index mass of <30 kg/m(2) . Liver biopsies were assessed by one pathologist blinded to clinical data. Histological features were non-alcoholic steatohepatitis (NASH), steatosis, hepatocellular ballooning, and liver fibrosis. Metabolic and hepatic profiles were analyzed, and lipid-lowering medication was recorded. OxLDL-ab levels were measured by ELISA. OxLDL-ab-based lipid indexes analyzed: oxLDL-ab/total cholesterol ratio; oxLDL-ab/LDL-c ratio; oxLDL-ab/high-density lipoprotein cholesterol (HDL-c) ratio; and oxLDL-ab/oxLDL ratio. RESULTS: Lean-NAFLD patients presented 26.5% (9/34) of NASH. OxLDL-ab/HDL-c ratio (r = 0.570; n = 34; P = 0.001) correlated with NAS score and was the only variable associated with NASH in the multivariate analysis [odds ratio, OR, 1.10 (95% confidence interval, CI: 1.01-1.21); P = 0.039]. Severe steatosis was present in 41.2% (14/34) of lean-NAFLD patients. OxLDL-ab/HDL-c ratio was higher in patients with grade-III steatosis (54.9 (37.3-124.6)) than those with grade II (37.1 (20.2-71.1)) and grade I (17.7 (13.1-22.8)) (P = 0.018). Hepatocellular ballooning was present in 20.6% (7/34) of lean-NAFLD patients, and OxLDL-ab/HDL-c ratio (OR 1.03 [95% CI: 1.01-1.05]; P = 0.050) was independently associated with histological features. OxLDL-ab/HDL-c ratio was higher in patients with advanced fibrosis (39.8 (22.9-121.6) vs 17.7 (13.9-30.9); P = 0.025), increasing gradually with the fibrosis stage (P = 0.042) and remained in the final multivariate model [OR 1.05 (95% CI: 1.00-1.11); P = 0.05]. However, in obese-NAFLD patients, oxLDL/HDL-c ratio was not associated with histological features. CONCLUSIONS: Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio could represent an interesting biomarker associated with NASH, hepatocellular ballooning, and liver fibrosis, in lean patients. OxLDL-ab/HDL-c could play an important role for distinguishing patients with and without NAFLD complications.

[Non-bacterial chronic osteomyelitis: Experience in a tertiary hospital]. / Osteomielitis crónica no bacteriana: experiencia en un hospital terciario.

INTRODUCTION: Non-bacterial chronic osteomyelitis (NBCO) is an autoinflammatory disease that presents with recurrent bouts of bone inflammation in the absence of microbiological isolation. It is a diagnosis of exclusion. Its treatment was classically based on the use of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, although nowadays bisphosphonates or anti-tumour necrosis factor-α (anti-TNF) drugs are frequently used with good results. The objective of the study is to describe our experience in the diagnosis and treatment of patients with NBCO. PATIENTS AND METHODS: Retrospective chart review of patients with NBCO followed up in a tertiary centre between 2008 and 2015. RESULTS: A total of 7 patients with NBCO were recorded. Four were female and the median age was 10 years (IQR 2). The most common complaint was pain that interfered with sleep in 5 of the patients. Six patients had multifocal lesions at diagnosis. Bone biopsy demonstrated neutrophilic or lymphocytic infiltration and sclerosis in 6 patients. Four patients received antibiotics and NSAIDs without clinical response. Five received a short course of prednisone with an adequate control of symptoms, but only one of them maintained remission after corticosteroid suspension. Five patients received bisphosphonates with disease remission in 3 of them. The other 2 showed an inadequate response to pamidronate and were started on anti-TNF therapy (etanercept, infliximab or adalimumab), remaining asymptomatic at present. CONCLUSIONS: Our series, although limited, confirms the effectiveness and safety of bisphosphonate and anti-TNF therapy for children with NBCO.

[Burkitt's lymphoma presenting as an intermittent limp]. / Cojera como forma de debut de un linfoma Burkitt.

Musculoskeletal pain is a frequent complaint in pediatrics usually related to benign conditions. However, it may also represent the initial symptom of serious diseases such as infections, malignancies or orthopedic emergencies. We present the case of a child diagnosed with Burkitt's lymphoma whose initial presentation was a limp. This is, to the best of our knowledge, the first case reported in the literature with this type of debut. This case illustrates the importance of including neoplasms in the differential diagnosis of atypical musculoskeletal pain, since early diagnosis can significantly improve their prognosis.

Cojera como forma de debut de un linfoma Burkitt / Burkitt's lymphoma presenting as an intermittent limp

Los dolores musculoesqueléticos son un motivo de consulta frecuente en Pediatría. En la mayoría de las ocasiones se trata de síntomas inespecíficos sin relación con enfermedades graves, aunque pueden representar el síntoma inicial de procesos que requieran una atención inmediata como son infecciones, neoplasias o urgencias ortopédicas. Este caso clínico ilustra la importancia de incluir en el diagnóstico diferencial del dolor musculoesquelético de evolución atípica a las neoplasias, dado que un diagnóstico precoz puede mejorar significativamente su pronóstico(AU)

Musculoskeletal pain is a frequent complaint in pediatrics usually related to benign conditions. However, it may also represent the initial symptom of serious diseases such as infections, malignancies or orthopedic emergencies. We present the case of a child diagnosed with Burkitt's lymphoma whose initial presentation was a limp. This is, to the best of our knowledge, the first case reported in the literature with this type of debut. This case illustrates the importance of including neoplasms in the differential diagnosis of atypical musculoskeletal pain, since early diagnosis can significantly improve their prognosis(AU)

Hipertensión secundaria grave como presentación de un caso de enfermedad de Takayasu, con mejoría angiográfica tras tratamiento médico / A case of Takayasu’s disease presenting as severe secondary hypertension, with angiographic improvement following medical treatment

No disponible

No disponible